REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company’s Strategic Advisory Board (SAB), joining John Maraganore, PhD, the founder and former Chief Executive Officer of Alnylam Pharmaceuticals.

加利福尼亚州红木城，2024年2月20日（环球通讯社）--领先的酶工程公司Codexis，Inc.（纳斯达克：CDXS）今天宣布任命Masad Damha博士和Jim Lalonde博士为公司战略咨询委员会（SAB）成员，加入Alnylam Pharmaceuticals创始人兼前首席执行官John Maraganore博士的行列。

This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform. “We are thrilled to have Masad and Jim lend their decades of experience in oligonucleotide research and development to our Strategic Advisory Board,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis.

该委员会目前由寡核苷酸合成和制造领域的专家组成，旨在帮助指导公司的战略方向，为Codexis的ECO synthesis™制造平台的持续开发提供重要见解。Codexis研究高级副总裁Stefan Lutz博士说：“我们很高兴Masad和Jim将他们数十年的寡核苷酸研究和开发经验提供给我们的战略咨询委员会。”。

“We now have Board representation across research, development, manufacturing, and commercialization, and with the forthcoming addition of our ECO Synthesis™ Innovation Lab at our headquarters, we’re confident that we’ll continue to see rapid progress toward our anticipated technical milestones and remain on track to initiate early access customer testing in the second half of this year.”   Masad Damha, PhD, is the Distinguished James McGill Professor at McGill University.

“我们现在在研究、开发、制造和商业化方面拥有董事会代表，随着总部即将增加我们的ECO Synthesis™创新实验室，我们有信心继续看到在实现预期的技术里程碑方面取得快速进展，并保持在今年下半年启动早期访问客户测试的轨道上。”马萨德·达哈博士是麦吉尔大学杰出的詹姆斯·麦吉尔教授。

His research has been instrumental in the development of new therapeutic drugs based on RNA targeting and gene editing, and he has authored more than 200 publications. Dr. Damha is a co-founder of Anagenis, Inc., a start-up with proprietary antisense technologies (ANA and FANA). His FANA technology is being applied by multiple research laboratories and industries to assess and develop modified oligonucleotides against several biological targets, including cancer and inf.

他的研究有助于开发基于RNA靶向和基因编辑的新型治疗药物，他撰写了200多篇出版物。Damha博士是Angenis，Inc.的联合创始人，Angenis，Inc.是一家拥有专有反义技术（ANA和FANA）的初创公司。他的FANA技术正在被多个研究实验室和行业应用，以评估和开发针对多种生物靶标的修饰寡核苷酸，包括癌症和inf。